High-Throughput Ex Vivo Drug Testing Identifies Potential Drugs and Drug Combinations for NRAS-Positive Malignant Melanoma

Three patient-derived cancer cells (PDCs) were established from NRAS Q61-positive metastatic melanoma patients. The response of PDCs and five established melanoma cell lines was evaluated toward a panel of 527 oncology drugs using high-throughput drug sensitivity and resistance testing.